Cited by 55Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsHealth Promotion and Cardiovascular Prevention

Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review

Open access
Sandhu, Paramjit K, Musaad, Salma M A, Remaley, Alan T, Buehler, Stephanie S, Strider, Sonya, Derzon, James H, Vesper, Hubert W, Ranne, Anne +2 more·2016·The Journal of Applied Laboratory Medicine

Abstract

Background: Controversy exists about the incremental utility of nontraditional lipid biomarkers [e.g., apolipoprotein (apo) B, apo A-I, and non-HDL-C] in improving cardiovascular disease (CVD) risk prediction when added to a conventional model of traditional risk factors (e.g., total cholesterol, LDL cholesterol, HDL cholesterol, sex, age, smoking status, and blood pressure). Here we present a systematic review that was conducted to assess the use of nontraditional lipid biomarkers including apo B, apo A-I, apo B/A-I ratio, and non-HDL-C in improving CVD risk prediction after controlling for the traditional risk factors in populations at risk for cardiovascular events. Content: This systematic review used the Laboratory Medicine Best Practices (LMBP™) A-6 methods. A total of 9 relevant studies published before and including July 2015 comprised the evidence base for this review. Results from this systematic review indicated that after the adjustment for standard nonlipid and lipid CVD risk factors, nontraditional apolipoprotein biomarkers apo B (overall effect = relative risk: 1.31; 95% CI, 1.22–1.40; 4 studies) and apo B/apo A-I ratio (overall effect = relative risk: 1.31; 95% CI, 1.11–1.38; 7 studies) resulted in significant improvement in long-term CVD risk assessment. Summary: Available evidence showed that nontraditional lipid biomarkers apo B and apo B/apo I ratio can improve the risk prediction for cardiovascular events after controlling for the traditional risk factors for the populations at risk. However, because of insufficient evidence, no conclusions could be made for the effectiveness of apo A-I and non-HDL-C lipid markers to predict the CVD events, indicating a need for more research in this field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/jalm.2016.021006

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 72 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Sandhu, P. K., Musaad, S. M. A., Remaley, A. T., Buehler, S. S., Strider, S., Derzon, J. H., Vesper, H. W., Ranne, A., Shaw, C. S., & Christenson, R. H.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • University of Illinois Urbana-Champaign (US)
  • National Institutes of Health (US)
  • Battelle (US)
  • RTI International (US)
  • University of Maryland, Baltimore (US)
Corresponding author
Sandhu, Paramjit K
Venue
The Journal of Applied Laboratory Medicine
Published
2016-09-01
Volume
1
Issue
2
Pages
214-229
ISSN
  • 2475-7241 (ISSN-L)
  • 2576-9456
OpenAlex
W2518743504
Cited by
55
References
72
Citations by year
2026: 4 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 2 · 2021: 9 · 2020: 8 · 2019: 4 · 2018: 8 · 2017: 4 · 2016: 1
FWCI
1.12
Type
journal article
Language
en
Open access
Locations
  • The Journal of Applied Laboratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Battelle
  • National Institutes of Health (CC999999)
  • Centers for Disease Control and Prevention
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
cardiovascular risk prediction, apolipoprotein B, apolipoprotein A-I, apolipoprotein B/A-I ratio, non-HDL cholesterol, traditional cardiovascular risk factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review